Bee Venom PLA2 Polypeptide Activates Regulatory T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, allergic diseases, and neurodegenerative diseases, such as multiple sclerosis, allergic asthma, and Parkinson's disease, often have limited efficacy and are associated with adverse effects, and there is a need for alternative therapies that can specifically target abnormal suppression of regulatory T cell activity.
Innovation Solution
A pharmaceutical composition containing a polypeptide with a bee venom-PLA2 amino acid sequence exclusive of a leader sequence, which activates regulatory T cells, thereby inhibiting Th1/Th17 differentiation and alleviating symptoms of these diseases without the risks associated with unpurified bee venom.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unpurified bee venom is used to treat diseases, then therapeutic effects are achieved, but safety risks and adverse effects increase
Solution Approach 1:
The patent extracts and isolates the specific active component BV-PLA2 from crude bee venom. This purification process removes harmful substances while retaining the therapeutic activity, thereby resolving the contradiction between therapeutic effect and safety risk.
Solution Approach 2:
The patent segments bee venom into its constituent components and identifies BV-PLA2 as the specific active ingredient responsible for therapeutic effects. This segmentation allows for selective use of the beneficial component while eliminating harmful elements.
2Reliability
If conventional therapies for autoimmune diseases are used, then treatment is provided, but efficacy is limited and adverse effects occur
Solution Approach 1:
The patent changes the therapeutic parameter from conventional non-specific immunosuppressants to the specific enzyme BV-PLA2 that targets regulatory T cell dysfunction. This parameter change provides both improved efficacy and reduced adverse effects by addressing the root cause rather than suppressing the entire immune system.
3Reliability
If regulatory T cell activity is not adequately activated, then immune tolerance is compromised, but excessive activation may cause immune suppression
Solution Approach 1:
The patent utilizes BV-PLA2 as a feedback mechanism that specifically targets and corrects regulatory T cell dysfunction. The enzyme acts on the specific molecular defect in Treg cells, providing precise correction without causing excessive immune suppression, thereby maintaining the balance between immune tolerance and immune function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively increases CD4+CD25+Foxp3+ Treg cells, inhibits Th1/Th17 differentiation, and reduces inflammatory cytokines, providing therapeutic benefits for autoimmune, allergic, and neurodegenerative diseases while minimizing adverse effects.
Implementation Method 1
bee venom-phospholipase A2 (BV-PLA2) as an active ingredient
Implementation Method 2
inhibiting Th1/Th17 differentiation
Data Source
AI summary
The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.